muscular
dystrophi
md
group
differ
inherit
disord
character
progress
weak
degener
muscl
fiber
duchenn
muscular
dystrophi
dmd
one
common
singlegen
disord
human
affect
newborn
male
symptom
start
emerg
around
age
year
includ
difficulti
walk
result
patient
wheelchairbound
age
case
xchromosom
link
recess
disord
aris
due
mutat
dystrophin
dmd
gene
dmd
gene
exon
approxim
kb
long
transcript
make
largest
known
gene
human
dmd
encod
dystrophin
protein
express
sarcolemma
skelet
cardiac
muscl
fiber
dystrophin
membranesupport
protein
connect
muscl
fiber
cytoskeleton
extracellular
matrix
ecm
enorm
size
gene
reason
hotspot
mutat
compar
gene
triplet
codon
mrna
preserv
mostli
lead
loss
dystrophin
subsequ
loss
function
mutat
known
outoffram
mutat
disrupt
open
read
frame
orf
prevent
dystrophin
express
sometim
orf
preserv
despit
presenc
mutat
known
infram
mutat
culmin
truncat
yet
function
dystrophin
lead
milder
form
disord
call
becker
muscular
dystrophi
bmd
bmd
patient
exhibit
later
onset
symptom
slow
progress
longer
lifespan
dmd
patient
case
symptom
mild
diagnosi
made
later
stage
life
commonli
use
option
amelior
dmd
symptom
administr
high
dose
glucocorticoid
although
strategi
prolong
ambul
extens
side
effect
deterior
qualiti
patient
life
variat
sever
disord
open
gateway
variou
therapeut
order
amelior
sever
milder
phenotyp
bmd
exampl
patient
exhibit
larg
delet
sometim
encompass
almost
half
gene
associ
milder
case
bmd
skip
mutat
exon
andor
adjac
exon
correct
open
read
frame
orf
therebi
lead
subsequ
express
dystrophin
sarcolemma
thought
molecular
mechan
underli
revert
fiber
rare
dystrophinposit
fiber
dmd
patient
anim
model
exon
skip
therapi
knock
rescu
target
protein
use
antisens
oligonucleotid
ao
restor
orf
although
strategi
applic
mutat
present
essenti
dystrophin
domain
sinc
exon
skip
without
alter
function
dystrophin
exon
skip
demonstr
system
rescu
delet
duplic
splice
site
nonsens
mutat
anim
model
main
aim
exonskip
therapi
slow
progress
dmd
interf
splice
event
therebi
convert
sever
symptom
milder
one
seen
bmd
thu
attract
therapeut
approach
treat
dmd
mani
improv
made
year
us
food
drug
administr
fda
condit
approv
sarepta
therapeut
ao
call
eteplirsen
treatment
dmd
target
exon
applic
approxim
patient
one
limit
exonskip
strategi
howev
limit
applic
addit
stabil
function
truncat
dystrophin
protein
unclear
importantli
multipl
exon
skip
multiexon
skip
could
address
issu
first
multiexon
skip
potenti
applic
dmd
patient
total
second
multiexon
skip
enabl
us
choos
truncat
dystrophin
protein
function
exampl
screen
sever
truncat
dystrophin
found
polyprolin
structur
present
hing
region
rod
domain
dystrophin
influenc
function
capac
replac
region
hing
significantli
improv
function
capac
prevent
muscl
degener
recent
multiexon
skip
demonstr
mous
dog
model
dmd
use
cocktail
ao
addit
cluster
regularli
interspac
short
palindrom
repeat
crispr
associ
protein
mediat
approach
employ
genet
remov
multipl
exon
dmd
gene
recent
develop
multiexon
skip
discuss
come
section
addit
discuss
regulatori
challeng
associ
cocktail
ao
approach
ao
short
synthet
nucleic
acid
sequenc
bp
long
select
hybrid
target
mrna
sequenc
figur
modif
made
phosphat
backbon
sugar
ring
chang
solubl
potenc
bind
stabil
figur
modif
increas
affin
ao
target
rna
also
protect
ao
nucleas
degrad
prevent
interact
spliceosom
machineri
region
ao
therebi
result
initi
splice
phosphorodiamid
morpholino
oligom
pmo
morpholino
one
promis
ao
chemic
modif
made
backbon
replac
phosphodiest
backbon
phosphorodiamid
linkag
make
pmo
unrecogniz
nucleas
thu
greatli
enhanc
stabil
previou
experi
carri
use
pmo
success
demonstr
restor
dystrophin
express
multipl
muscl
group
follow
system
deliveri
sever
murin
dog
model
use
ao
therapi
dmd
advantag
compar
use
diseas
dystroph
fiber
take
ao
compar
healthi
fiber
addit
recent
studi
show
effici
pmo
deliveri
muscl
depend
firstli
accumul
retent
pmo
within
inflammatori
foci
associ
dystroph
lesion
secondli
fusion
myoblast
contain
pmo
repair
myofib
eteplirsen
exondi
sarepta
therapeut
cambridg
usa
pmo
select
bind
exon
premrna
restor
open
read
frame
induc
exonskip
produc
truncat
protein
condit
approv
food
drug
administr
fda
eteplirsen
rescu
dystrophin
level
rang
healthi
muscl
contrast
expect
valu
regain
muscl
function
three
year
administr
eteplirsen
mgkg
mgkg
advers
effect
immun
activ
hypersensit
report
howev
fda
approv
eteplirsen
remain
controversi
approv
weak
evid
support
effect
term
restor
dystrophin
express
sever
pmo
target
dmd
exon
includ
golodirsen
sarepta
therapeut
cambridg
usa
ns
pharma
paramu
nj
usa
current
clinic
trial
target
exon
skip
exon
approxim
dmd
patient
mutat
would
potenti
treatabl
advantag
pmo
chargeneutr
backbon
cellpenetr
moieti
easili
conjug
power
tool
induc
multipl
exon
skip
figur
octa
guanidineconjug
pmo
also
call
vivomorpholino
vpmo
possess
cellpenetr
octaguanidinium
dendrim
vpmo
shown
effici
splice
modul
target
skip
dmd
exon
dystroph
dog
exon
mice
peptideconjug
pmo
ppmo
also
shown
effici
rescu
cardiac
skelet
muscl
mdx
mice
dog
model
first
system
multiexon
skip
demonstr
dmd
dog
model
larg
size
dystroph
dog
suitabl
clinic
grade
detail
analysi
compar
anim
model
dog
model
advantag
mous
model
repres
human
diseas
close
canin
xlink
muscular
dystrophi
cxmd
model
harbor
point
mutat
intron
lead
exon
delet
figur
restor
orf
requir
exon
splice
henc
model
use
test
efficaci
safeti
multiexon
skip
particular
studi
ao
design
way
bind
exon
result
skip
order
correct
read
frame
shown
figur
exon
encod
hing
domain
result
spontan
skip
cocktail
ao
administ
variou
dosag
cxmd
dog
model
intraven
inject
morpholino
cocktail
dosag
mgkg
weekli
week
show
increas
dystrophinposit
fiber
similarli
dosag
increas
mgkg
weekli
week
improv
histopatholog
observ
clinic
grade
morpholino
treat
dog
also
show
improv
walk
run
abil
pmo
conjug
peptid
ppmo
abil
penetr
cell
order
induc
dystrophin
express
effect
order
test
effici
safeti
system
deliveri
ppmo
total
concentr
mgkg
administ
time
consecut
cxmd
dog
use
western
blot
compar
dystrophin
level
observ
dystrophin
level
treat
dog
increas
equal
total
dystrophin
level
wt
dog
cardiac
muscl
addit
skelet
muscl
exon
skip
along
spontan
delet
exon
disturb
orf
also
immunohistochemistri
myocardium
muscl
reveal
dystrophinposit
fiber
observ
week
last
system
inject
dmd
patient
show
vacuol
degener
cardiac
purkinj
fiber
supposedli
due
loss
dystrophin
immunohistochemistri
fiber
reveal
amelior
vacuol
degener
cxmd
dog
degener
significantli
reduc
intracoronari
inject
ic
intraven
iv
inject
peptid
tendenc
behav
antigen
trigger
immun
respons
howev
system
administr
activ
immun
system
verifi
leucocyt
count
treat
dog
though
limit
dog
use
studi
efficaci
intraven
administr
toxic
report
thu
infer
multiexon
skip
use
ppmo
effici
restor
dystrophin
express
without
minim
immun
respons
exon
exon
found
mutat
hotspot
dmd
gene
cover
approxim
patient
respect
accord
medic
case
studi
male
exhibit
asymptomat
phenotyp
delet
exon
spite
high
level
serum
creatin
kinas
suffer
muscl
atrophi
weak
development
delay
age
age
minor
chang
size
muscl
fiber
yet
sign
necrot
tissu
cellular
infiltr
patient
turn
physic
examin
reveal
normal
serum
creatin
kinas
level
propos
presenc
absenc
activ
bind
site
ab
may
respons
determin
mild
phenotyp
ab
ntermin
domain
ab
patient
whose
exon
skip
lack
ab
show
presenc
report
suggest
essenti
actin
bind
abil
dystrophin
necessari
maintain
dystrophin
function
skelet
muscl
lack
therefor
associ
becker
phenotyp
accord
previou
studi
mutat
region
gene
around
dystrophin
level
essenti
prevent
dystrophi
muscl
howev
patient
current
studi
show
normal
level
yet
express
mild
phenotyp
contradict
find
result
differ
mutat
region
mutat
actin
bind
region
normal
associ
sever
bmd
phenotyp
case
studi
conclud
delet
exon
may
produc
low
quantiti
structur
stabl
protein
normal
dystrophin
level
suffici
maintain
muscl
integr
given
protein
function
sinc
skip
exon
cover
mutat
hotspot
seem
promis
therapeut
target
howev
studi
requir
test
therapeut
effici
skip
exon
anoth
emerg
approach
induc
multipl
exon
skip
genom
edit
cluster
regularli
interspac
short
palindrom
repeat
crispr
system
crispr
work
adapt
immun
system
phage
infect
bacteria
make
use
singl
guid
rna
sgrna
guid
endonucleas
specif
genom
sequenc
result
cleavag
crisprca
system
promis
approach
toward
correct
mani
genet
defect
report
patient
exon
skip
display
appar
phenotyp
make
multiexon
skip
exon
effect
approach
treat
mutat
system
use
induc
skip
exon
dmd
gene
healthi
human
induc
pluripot
stem
cell
ipsc
analyz
effect
delet
achiev
use
compar
follow
strategi
gener
del
ipsc
target
intron
subsequ
delet
exon
del
ipsc
target
intron
subsequ
delet
exon
del
ipsc
target
intron
subsequ
delet
exon
mediat
edit
strategi
produc
differ
modif
del
retain
correct
del
retain
correct
del
retain
three
howev
interest
note
although
open
read
frame
maintain
delet
exon
produc
least
stabl
protein
minim
restor
function
due
delet
amino
acid
led
protein
misfold
subsequ
degrad
del
strategi
could
fulli
restor
function
control
level
del
effect
strategi
gener
truncat
protein
lack
amino
acid
restor
function
ipscderiv
cardiomyocyt
conclus
strategi
delet
exon
ideal
candid
target
dmd
popul
caus
mutat
patient
infram
mutat
exon
skip
express
mild
bmd
asymptomat
phenotyp
interestingli
exon
dmd
gene
cover
mutat
hotspot
therefor
multiexon
skip
exon
use
ao
promis
strategi
could
treat
almost
dmd
patient
mice
harbor
delet
mutat
exon
therefor
good
model
test
exon
skip
effici
intramuscular
system
administr
vpmo
skip
entir
region
compris
exon
test
mice
order
dosag
cocktail
target
exon
exon
mgkg
total
administ
everi
week
show
effici
induc
skip
exon
histopatholog
muscl
reveal
amelior
muscl
lesser
degener
muscl
fiber
system
deliveri
also
ensur
improv
muscl
function
detect
immunoreact
compar
nontreat
mice
evid
toxic
administr
regimen
howev
studi
need
test
dose
escal
reduct
well
chronic
toxic
assess
order
assess
effici
system
remov
multipl
dmd
exon
adenoassoci
viru
mediat
deliveri
use
mice
mice
harbor
nonsens
mutat
exon
least
exon
exon
need
remov
make
appropri
model
test
multipl
exon
skip
figur
due
limit
carri
capac
aav
kb
dualvector
strategi
administ
local
tibiali
anterior
ta
mous
model
involv
nucleas
vector
express
set
vector
consist
two
singleguid
rna
sgrna
shown
figur
sgrna
direct
cleavag
dna
within
intron
region
exon
exon
dna
repair
use
nonhomolog
end
join
nhej
result
delet
kb
genom
dna
bp
encod
mrna
immunostain
muscl
crosssect
reveal
myofib
express
dystrophin
exon
excis
use
local
deliveri
dual
vector
approach
improv
muscl
function
ta
system
deliveri
dual
vector
ensur
dystrophin
express
total
cardiac
myofib
heart
week
posttransduct
use
dualvector
strategi
advantag
flexibl
offer
variat
ratio
target
compon
nucleas
vector
may
enhanc
effici
vivo
transduct
satellit
cell
muscl
stem
cell
ensur
perman
correct
dystrophin
protein
thu
continu
express
howev
studi
use
system
target
satellit
cell
yet
carri
studi
necessari
order
target
mutat
hotspot
dmd
eg
exon
exon
ensur
bodywid
dystrophin
express
potenti
offtarget
need
care
assess
everi
geneedit
strategi
ensur
longterm
safeti
efficaci
antisensemedi
exon
skip
therapeut
strategi
develop
hold
promis
therapeut
potenti
howev
today
date
certain
barrier
still
preval
especi
natur
person
therapi
mutat
caus
dmd
vari
uniqu
dmd
patient
eteplirsen
drug
approv
fda
still
hold
controversi
regard
approv
wherea
anoth
drug
drisapersen
reject
multipl
exon
skip
attract
approach
overcom
applic
issu
howev
cocktail
ao
approach
face
addit
regulatori
challeng
current
regul
requir
ao
cocktail
compon
possibl
cocktail
combin
undergo
toxicolog
test
creat
regulatori
barrier
enorm
expens
intimid
one
must
note
everi
part
cocktail
benefici
everi
patient
exampl
ideal
ao
cocktail
administ
patient
delet
exon
everi
part
cocktail
serv
molecular
benefit
individu
patient
therebi
make
unchart
territori
fda
anoth
exampl
exon
need
skip
togeth
restor
read
frame
dmd
exon
delet
eg
dystroph
dog
henc
ao
target
exon
combin
therapeut
effect
individu
oligo
clinic
effect
current
drug
approv
system
design
evalu
circumst
like
scenario
requir
signific
chang
promot
cocktail
approach
sinc
ao
base
exonskip
therapi
target
premrna
limit
persist
repeat
inject
necessari
system
robust
tool
edit
dna
shown
promis
result
perman
correct
mutat
dmd
gene
mous
model
humanderiv
ipsc
howev
one
potenti
issu
use
system
includ
occurr
offtarget
cleavag
although
concern
report
studi
use
ipsc
modifi
geneedit
system
aavmedi
system
deliveri
lead
robust
express
year
increas
risk
one
also
note
may
pose
safeti
concern
clinic
applic
nevertheless
shown
promis
result
correct
mutat
dmd
gene
current
clinic
trial
focus
singleexon
skip
success
multiexon
skip
reli
futur
investig
chang
stanc
regulatori
bodi
continu
develop
modif
aobas
multiexon
skip
therapi
promis
safe
therapeut
strategi
treat
major
dmd
patient
futur
